Neoleukin Therapeutics Alpha and Beta Analysis
| NLTXDelisted Stock | USD 0.69 0.01 1.43% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Neoleukin Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Neoleukin Therapeutics over a specified time horizon. Remember, high Neoleukin Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Neoleukin Therapeutics' market risk premium analysis include:
Beta (0.52) | Alpha (0.11) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Neoleukin |
Neoleukin Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Neoleukin Therapeutics market risk premium is the additional return an investor will receive from holding Neoleukin Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Neoleukin Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Neoleukin Therapeutics' performance over market.| α | -0.11 | β | -0.52 |
Neoleukin Therapeutics Fundamentals Vs Peers
Comparing Neoleukin Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Neoleukin Therapeutics' direct or indirect competition across all of the common fundamentals between Neoleukin Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Neoleukin Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Neoleukin Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Neoleukin Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Neoleukin Therapeutics to competition |
| Fundamentals | Neoleukin Therapeutics | Peer Average |
| Return On Equity | -0.38 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Current Valuation | (35.02 M) | 16.62 B |
| Shares Outstanding | 2.35 M | 571.82 M |
| Shares Owned By Insiders | 16.46 % | 10.09 % |
| Shares Owned By Institutions | 45.58 % | 39.21 % |
| Number Of Shares Shorted | 26.4 K | 4.71 M |
Neoleukin Therapeutics Opportunities
Neoleukin Therapeutics Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Neoleukin Therapeutics Shares Rise Premarket on Reverse Merger Deal NLTX | 07/18/2023 |
About Neoleukin Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Neoleukin or other delisted stocks. Alpha measures the amount that position in Neoleukin Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Neoleukin Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Neoleukin Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neoleukin Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Neoleukin Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Neoleukin Therapeutics. Please utilize our Beneish M Score to check the likelihood of Neoleukin Therapeutics' management manipulating its earnings.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Neoleukin Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |